Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine

被引:51
作者
Demyttenaere, K
Mesters, P
Boulanger, B
Dewe, W
Delsemme, MH
Gregoire, J
Van Ganse, E
机构
[1] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[2] Eli Lilly Belgium, Brussels, Belgium
[3] Lilly Res Labs, Brussels, Belgium
[4] Catholic Univ Louvain, Fac Psychol, Louvain, Belgium
[5] Univ Lyon, Fac Pharmacol Clin, EVG, Lyon, France
关键词
depressed patients; amitriptyline; fluoxetine;
D O I
10.1016/S0165-0327(00)00225-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Non-compliance presents a constant challenge to effective therapy, Many studies only investigate early treatment discontinuation and not other measures like adherence to treatment regimen. We compared adherence in depressed patients using either a selective serotonin reuptake inhibitor (fluoxetine) or a tricyclic antidepressant (amitriptyline), and examined its clinical relevance through adverse events, drop-out rates, and outcome. Adherence was measured electronically with the MEMS (Medication Event Monitoring System). Design: Nine-week double blind, randomized controlled trial. Setting: Ambulatory psychiatric care. Patients: Random sample of 66 depressed (DSM-RI-R criteria) patients. Intervention: Fluoxetine 20 mg or amitriptyline 150 mg. Main outcome measures: Time course of adherence and its relation to severe adverse events, drop-outs and outcome. Results: Non-adherence to the treatment regimen occurred frequently in both treatment groups: 31% of patients had at least one 3-day drug holiday, and 34% of patients had at least one episode of three pills in a 24-h period. Over-consumption occurred more frequently during the -early phases of treatment while underconsumption occurred more frequently during the later phases. Patients on amitriptyline (P = 0.03) and patients with a higher pill intake (P = 0.01) experienced more severe adverse events. Patients on amitriptyline (P = 0.009) and patients with a lower adherence to the treatment regimen (P = 0.004) discontinued from treatment more frequently. The final Hamilton score was significantly predicted by a longer duration of treatment and by a better adherence, but only in amitriptyline. users. Conclusions: Non-adherence to the treatment regimen has important clinical consequences. Pharmacodynamics. and human behavior predict risk for severe adverse events and drop-outs. Moreover, in amitriptyline users but not in fluoxetine users, better adherence predicts a better outcome. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:243 / 252
页数:10
相关论文
共 26 条
[1]  
[Anonymous], 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), V4th
[2]  
Association A.P., 1987, Diagnostic and Statistical Manual of Mental Disorders-Revision
[3]   FLUOXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
HEEL, RC ;
LEWIS, SP .
DRUGS, 1986, 32 (06) :481-508
[4]  
Boyer WF, 1991, SELECTIVE SEROTONIN, P89
[5]   PATIENT COMPLIANCE WITH ONCE-DAILY AND TWICE-DAILY ORAL FORMULATIONS OF 5-ISOSORBIDE MONONITRATE - A COMPARATIVE-STUDY [J].
BRUN, J .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1994, 22 (05) :266-272
[6]   Serotonin reuptake inhibitor withdrawal [J].
Coupland, NJ ;
Bell, CJ ;
Potokar, JP .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (05) :356-362
[7]   COMPLIANCE DECLINES BETWEEN CLINIC VISITS [J].
CRAMER, JA ;
SCHEYER, RD ;
MATTSON, RH .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1509-1510
[8]   HOW OFTEN IS MEDICATION TAKEN AS PRESCRIBED - A NOVEL ASSESSMENT TECHNIQUE [J].
CRAMER, JA ;
MATTSON, RH ;
PREVEY, ML ;
SCHEYER, RD ;
OUELLETTE, VL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (22) :3273-3277
[9]   Compliance in depressed patients treated with fluoxetine or amitriptyline [J].
Demyttenaere, K ;
Van Ganse, E ;
Gregoire, J ;
Gaens, E ;
Mesters, P .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (01) :11-17
[10]   Noncompliance with antidepressants: who's to blame? [J].
Demyttenaere, K .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 :S19-S25